Skip to main content
. 2010 Sep 27;50(3):437–449. doi: 10.1093/rheumatology/keq287

Fig. 3.

Fig. 3

Clinical efficacy over 1 year in the ATTEST trial. ACR responses achieved over Year 1 of the ATTEST trial. Data are presented for the intent-to-treat population with a last observation carried forward analysis. aInfliximab was administered on Days 1, 15, 43, 85 and then every 56 days thereafter; abatacept dosing occurred at each visit day. Reproduced from Schiff et al. [46] copyright 2008, with permission from the BMJ Publishing Group Ltd.